A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

NCT07224672 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyloidosis

Interventions

DRUG: Belantamab mafodotin
DRUG: Cyclophosphamide
DRUG: Bortezomib
DRUG: Dexamethasone

Sponsor

GlaxoSmithKline